Perioperative atezolizumab + chemotherapy more than doubles event-free survival in resectable stage II–IIIB NSCLC
Patients with resectable stage II–IIIB non-small cell lung cancer (NSCLC) treated with perioperative atezolizumab plus platinum-based chemotherapy experienced a median event-free survival of 62.8 months compared with 34.9 months for patients receiving chemotherapy alone, according to final results from the Phase III IMpower030 trial.
A recent Phase III trial presented at the IASLC 2026 World Conference on Lung Cancer in Seoul has shown that perioperative atezolizumab combined with chemotherapy significantly improves event-free survival in resectable stage II–IIIB non-small cell lung cancer (NSCLC) patients. While the trial did not meet its statistical significance threshold, the results indicate clinically meaningful benefits in event-free survival, pathological response rates, and other important outcomes.
A median event-free survival of 62.8 months was observed in patients receiving the atezolizumab regimen compared to 34.9 months for those receiving chemotherapy alone. Pathological complete response rates were also substantially higher, reaching 29.6% with the atezolizumab regimen versus 8.5% with chemotherapy alone. These findings support the use of perioperative immunotherapy in resectable NSCLC patients.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
